ReviewBiomedicines2025
Gut Microbiota in Heart Failure-The Role of Inflammation.
Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Assessment of gastrointestinal health and the coagulation system in dogs with right-sided heart disease: an exploratory study.Journal of veterinary internal medicine · 2026Article
- Oral Health and Gut-Targeted Microbial Marker Changes Associated with Prolonged Hospitalization in Cardiac Patients: An Integrative Risk Analysis.Life (Basel, Switzerland) · 2026Article
- The gut-heart axis in atrial fibrillation: Pathophysiology, evidence, and therapeutic potential.Heart rhythm O2 · 2026Review
- Heart Failure in the Molecular Era: Redefining Our Understanding of Disease Mechanisms and Perspectives.Biomedicines · 2026Review
- Intestinal Fatty Acid Binding Protein (I-FABP) in Heart Failure: A Comprehensive Review of its Role as a Biomarker and Mediator in Cardiac Dysfunction.Current heart failure reports · 2026Review
- Assessing Venous Congestion in Heart Failure: A Review of Splanchnic, Cardiac, and Pulmonary Ultrasound: Part 2: Contrast-Enhanced Ultrasound and Shear Wave.Journal of clinical medicine · 2026Review
- Gut Microbiota and Short-Chain Fatty Acids in Cardiometabolic HFpEF: Mechanistic Pathways and Nutritional Therapeutic Perspectives.Nutrients · 2026Review
- Gut-Heart Axis and Infective Endocarditis: How Microbiota Dysbiosis Shapes Cardiovascular Risk and Infection Susceptibility.Journal of clinical medicine · 2026Review
- Gut Microbiota-Derived Metabolite and Heart Failure with Reduced Ejection Fraction (HFrEF): Elevated Trimethylamine N-Oxide (TMAO) as a Potential Biomarker.International journal of molecular sciences · 2026Article
- Investigating the gut microbiota in advanced heart failure and cardiac cachexia.Gut microbes reports · 2026Article
- Influence of Yoga-based cardiac rehabilitation on gut-microbiome diversity and Gut-Heart-Brain axis (YoGH-Biome) in heart failure: a study protocol.BMJ open sport & exercise medicine · 2026Article
- The gut-heart axis in heart failure: from bidirectional pathophysiological mechanisms to integrative therapeutic strategies.Frontiers in microbiology · 2026Review
- Gut microbiota dysbiosis-induced chronic inflammation as a driver of atherosclerosis: cellular crosstalk and host-microbe interactions.Frontiers in cellular and infection microbiology · 2026Review
- Neural-immune-cardiovascular axis: from mechanistic crosstalk to therapeutic targets in cardiovascular disease.Frontiers in immunology · 2026Review
- Heart Failure and Cognitive Impairment Through the Lens of the Gut Microbiome: A Narrative Review.Journal of personalized medicine · 2025Review
- The role of the gut microbiota and metabolites in heart failure and possible implications for treatment.Heart failure reviews · 2025Review
- Gut Microbiota Alterations in Heart Failure Patients: Insights from a Systematic Review.Journal of clinical medicine · 2025Review
- Targeting Gut Microbiome Dysbiosis as a Potentially Effective Therapeutic Approach for the Treatment of Heart Failure.Reviews in cardiovascular medicine · 2025Article
- A Systemic Perspective of the Link Between Microbiota and Cardiac Health: A Literature Review.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) has become an immense health concern affecting almost 1-2% of the population globally. It is a complex syndrome characterized by activation of the sympathetic nervous system and the Renin-Angiotensin-Aldosterone (RAAS) axis as well as endothelial dysfunction, oxidative stress, and inflammation. The recent literature points towards the interaction between the intestinal flora and the heart, also called the gut-heart axis. The human gastrointestinal tract is naturally inhabited by various microbes, which are distinct for each patient, regulating the functions of many organs. Alterations of the gut microbiome, a process called dysbiosis, may result in systemic diseases and have been associated with heart failure through inflammatory and autoimmune mechanisms. The disorder of intestinal permeability favors the translocation of microbes and many metabolites capable of inducing inflammation, thus further contributing to the deterioration of normal cardiac function. Besides diet modifications and exercise training, many studies have revealed possible gut microbiota targeted treatments for managing heart failure. The aim of this review is to demonstrate the impact of the inflammatory environment induced by the gut microbiome and its metabolites on heart failure and the elucidation of these novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.